MA32132B1 - Utilisation de ranolazine pour traiter la douleur - Google Patents
Utilisation de ranolazine pour traiter la douleurInfo
- Publication number
- MA32132B1 MA32132B1 MA33137A MA33137A MA32132B1 MA 32132 B1 MA32132 B1 MA 32132B1 MA 33137 A MA33137 A MA 33137A MA 33137 A MA33137 A MA 33137A MA 32132 B1 MA32132 B1 MA 32132B1
- Authority
- MA
- Morocco
- Prior art keywords
- ranolazine
- pain
- treatment
- patient
- visceral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne des procédés pour traiter un patient souffrant d'une douleur neuropathique ou nociceptive qui peut être de nature mécanique, viscérale et/ou inflammatoire, comprenant l'administration d'une quantité thérapeutiquement efficace de ranolazine à un patient qui en a besoin.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2669908P | 2008-02-06 | 2008-02-06 | |
US5743708P | 2008-05-30 | 2008-05-30 | |
PCT/US2009/033464 WO2009100380A1 (fr) | 2008-02-06 | 2009-02-06 | Utilisation de ranolazine pour traiter la douleur |
Publications (1)
Publication Number | Publication Date |
---|---|
MA32132B1 true MA32132B1 (fr) | 2011-03-01 |
Family
ID=40548472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA33137A MA32132B1 (fr) | 2008-02-06 | 2010-09-01 | Utilisation de ranolazine pour traiter la douleur |
Country Status (13)
Country | Link |
---|---|
US (1) | US20090203707A1 (fr) |
EP (1) | EP2252294A1 (fr) |
KR (1) | KR20110013348A (fr) |
CN (1) | CN101977605A (fr) |
AU (1) | AU2009212254A1 (fr) |
BR (1) | BRPI0908428A2 (fr) |
CA (1) | CA2713521A1 (fr) |
CO (1) | CO6290663A2 (fr) |
EA (1) | EA201070914A1 (fr) |
EC (1) | ECSP10010446A (fr) |
IL (1) | IL207292A0 (fr) |
MA (1) | MA32132B1 (fr) |
WO (1) | WO2009100380A1 (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8822473B2 (en) * | 2002-05-21 | 2014-09-02 | Gilead Sciences, Inc. | Method of treating diabetes |
KR101030943B1 (ko) | 2002-05-21 | 2011-04-28 | 씨브이 쎄러퓨틱스, 인코포레이티드 | 당뇨병 치료를 위한 라놀라진 등의 부분적 지방산 산화저해제 투여 |
US20090247535A1 (en) * | 2008-03-26 | 2009-10-01 | Duke University | Use of ranolazine for non-cardiovascular disorders |
JP2012526848A (ja) * | 2009-05-14 | 2012-11-01 | ギリアード サイエンシーズ, インコーポレイテッド | Cns障害の治療のためのラノラジン |
RS56410B1 (sr) * | 2009-07-27 | 2018-01-31 | Gilead Sciences Inc | Fuzionisana heterociklična jedinjenja kao modulatori jonskih kanala |
BR112012033402A2 (pt) | 2010-07-02 | 2017-01-24 | Gilead Sciences Inc | moduladores de canais de íons conforme os compostos heterocíclicos fundidos |
JP5934787B2 (ja) | 2011-05-10 | 2016-06-15 | ギリアード サイエンシーズ, インコーポレイテッド | イオンチャネルモジュレーターとしての縮合複素環式化合物 |
TW201837023A (zh) | 2011-07-01 | 2018-10-16 | 美商基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
NO3175985T3 (fr) | 2011-07-01 | 2018-04-28 | ||
KR101918375B1 (ko) | 2013-12-19 | 2018-11-13 | 길리애드 사이언시즈, 인코포레이티드 | 이온 채널 조정제로서의 융합된 헤테로시클릭 화합물 |
WO2017152062A1 (fr) | 2016-03-04 | 2017-09-08 | Gilead Sciences, Inc. | Compositions et combinaisons d'inhibiteurs de l'autotaxine |
US11261188B2 (en) | 2016-11-28 | 2022-03-01 | Praxis Precision Medicines, Inc. | Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel |
JP7105797B2 (ja) | 2016-11-28 | 2022-07-25 | プラクシス プレシジョン メディシンズ, インコーポレイテッド | 化合物及びその使用方法 |
WO2018148745A1 (fr) | 2017-02-13 | 2018-08-16 | Praxis Precision Medicines , Inc. | Composés et leurs méthodes d'utilisation |
WO2018187480A1 (fr) | 2017-04-04 | 2018-10-11 | Praxis Precision Medicines, Inc. | Composés et leurs méthodes d'utilisation |
WO2019035951A1 (fr) | 2017-08-15 | 2019-02-21 | Praxis Precision Medicines, Inc. | Composés et leurs méthodes d'utilisation |
AU2019278814A1 (en) | 2018-05-30 | 2020-12-17 | Praxis Precision Medicines, Inc. | Ion channel modulators |
US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
CN115038442A (zh) | 2019-11-27 | 2022-09-09 | 普拉西斯精密医药公司 | 离子通道调节剂的调配物及制备和使用离子通道调节剂的方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4657264A (en) * | 1985-11-01 | 1987-04-14 | Ingersoll-Rand Company | Fluid seal assembly with segmented sub-assembly |
ATE142497T1 (de) * | 1989-06-23 | 1996-09-15 | Syntex Inc | Ranolazin und verwandte piperazine zur behandlung von geweben, von physischen oder chemischen schäden betroffen |
US5455045A (en) * | 1993-05-13 | 1995-10-03 | Syntex (U.S.A.) Inc. | High dose formulations |
US6479496B1 (en) * | 1998-09-10 | 2002-11-12 | Cv Therapeutics, Inc. | Methods for treating angina with ranolazine |
US6303607B1 (en) * | 1998-09-10 | 2001-10-16 | Cv Therapeutics, Inc. | Method for administering a sustained release ranolanolazine formulation |
BR0108452A (pt) * | 2000-02-18 | 2003-04-01 | Cv Therapeutics Inc | Inibidores da oxidação parcial de ácido graxo no tratamento de insuficiência cardìaca congestiva |
US20030220344A1 (en) * | 2002-04-04 | 2003-11-27 | Luiz Belardinelli | Method of treating arrhythmias |
KR101030943B1 (ko) * | 2002-05-21 | 2011-04-28 | 씨브이 쎄러퓨틱스, 인코포레이티드 | 당뇨병 치료를 위한 라놀라진 등의 부분적 지방산 산화저해제 투여 |
US8822473B2 (en) * | 2002-05-21 | 2014-09-02 | Gilead Sciences, Inc. | Method of treating diabetes |
RU2384332C2 (ru) * | 2005-01-06 | 2010-03-20 | Си Ви Терапьютикс, Инк. | Фармацевтические препаративные формы замедленного высвобождения |
CA2624361A1 (fr) * | 2005-11-21 | 2007-05-31 | The Board Of Trustees Of The University Of Alabama For And On Behalf Of The University Of Alabama | Procedes utilisant des composes de petites molecules a des fins de neuroprotection |
KR20090033417A (ko) * | 2006-07-27 | 2009-04-03 | 씨브이 쎄러퓨틱스, 인코포레이티드 | 중독의 치료에서의 aldh-2 저해제 |
WO2008100992A1 (fr) * | 2007-02-13 | 2008-08-21 | Cv Therapeutics, Inc. | Solutions intraveineuses comprenant de la ranolazine |
US20080248112A1 (en) * | 2007-02-13 | 2008-10-09 | Brent Blackburn | Use of ranolazine for the treatment of coronary microvascular diseases |
JP2010523590A (ja) * | 2007-04-05 | 2010-07-15 | ギリアード・パロ・アルト・インコーポレイテッド | Aldh−2阻害剤としてのキナゾリノン誘導体 |
KR20100015685A (ko) * | 2007-04-12 | 2010-02-12 | 씨브이 쎄러퓨틱스, 인코포레이티드 | 인슐린 분비 강화를 위한 라놀라진 |
BRPI0820440A2 (pt) * | 2007-11-06 | 2015-05-26 | Cv Therapeutics Inc | Inibidores aldh-2 no tratamento de desordens psiquiátricas |
-
2009
- 2009-02-06 EA EA201070914A patent/EA201070914A1/ru unknown
- 2009-02-06 EP EP09707821A patent/EP2252294A1/fr not_active Withdrawn
- 2009-02-06 AU AU2009212254A patent/AU2009212254A1/en not_active Abandoned
- 2009-02-06 CA CA2713521A patent/CA2713521A1/fr not_active Abandoned
- 2009-02-06 BR BRPI0908428A patent/BRPI0908428A2/pt not_active Application Discontinuation
- 2009-02-06 WO PCT/US2009/033464 patent/WO2009100380A1/fr active Application Filing
- 2009-02-06 KR KR1020107019622A patent/KR20110013348A/ko not_active Application Discontinuation
- 2009-02-06 CN CN2009801040287A patent/CN101977605A/zh active Pending
- 2009-02-06 US US12/367,403 patent/US20090203707A1/en not_active Abandoned
-
2010
- 2010-07-29 IL IL207292A patent/IL207292A0/en unknown
- 2010-08-13 CO CO10099978A patent/CO6290663A2/es not_active Application Discontinuation
- 2010-09-01 MA MA33137A patent/MA32132B1/fr unknown
- 2010-09-03 EC EC2010010446A patent/ECSP10010446A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2009212254A1 (en) | 2009-08-13 |
KR20110013348A (ko) | 2011-02-09 |
US20090203707A1 (en) | 2009-08-13 |
ECSP10010446A (es) | 2010-10-30 |
CN101977605A (zh) | 2011-02-16 |
IL207292A0 (en) | 2010-12-30 |
EP2252294A1 (fr) | 2010-11-24 |
CA2713521A1 (fr) | 2009-08-13 |
CO6290663A2 (es) | 2011-06-20 |
BRPI0908428A2 (pt) | 2015-12-08 |
WO2009100380A1 (fr) | 2009-08-13 |
EA201070914A1 (ru) | 2011-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA32132B1 (fr) | Utilisation de ranolazine pour traiter la douleur | |
MA31822B1 (fr) | Compositions et methodes d'utilisation de peptides pro-ilot et leur analogues | |
MA38144A1 (fr) | Compositions et procédés pour le traitement de protéinopathies | |
MA31605B1 (fr) | Anticorps anti-cd79b humanisés, immunoconjugués, et procédés d'utilisation | |
MA30632B1 (fr) | Anticorps humanisé | |
TW200733976A (en) | Method for the treatment of cognitive dysfunction | |
MX2022005782A (es) | Anticuerpos monoclonales contra la proteina amiloide beta y usos de los mismos. | |
TN2010000068A1 (en) | Anticorps anti-cd37 | |
MX2009012950A (es) | ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS. | |
BRPI0813699A2 (pt) | Formulações de proteína de fusão glp-1-fc | |
SG164369A1 (en) | Human anti-b7rp1 neutralizing antibodies | |
MA31202B1 (fr) | Procede de traitement du cancer | |
EA201001865A1 (ru) | Противовоспалительные агенты | |
WO2008043107A3 (fr) | Utilisation d'antagonistes des jonctions occlusives pour traiter les affections abdominales inflammatoires | |
MA33743B1 (fr) | Compositions comprenant du tramadol et du célécoxib dans le traitement de la douleur | |
MA32056B1 (fr) | Suspension pharmaceutique orale contenant du paracetamol et de l'ibuprofene | |
WO2011026125A3 (fr) | Compositions pharmaceutiques à rétention gastrique permettant une libération immédiate et prolongée d'acétaminophène | |
MA37946A1 (fr) | Traitement de la polyarthrite rhumatoïde | |
MA33571B1 (fr) | Traitement de cellules tumorales astrocytaires avec des inhibiteurs de recepteurs d'endotheline | |
EP2567701A3 (fr) | Traitement de l'insuffisance cardiaque chez les animaux mammifères non humains par un antagoniste de l'aldostérone. | |
MA31941B1 (fr) | Bis-pyridylpyridones en tant qu'antagonistes du récepteur 1 de l'hormone de concentration de la mélanine | |
MA33839B1 (fr) | Compositions et procédés destinés à diagnostiquer et à traiter des tumeurs | |
MA33470B1 (fr) | Polythérapie à base d'un anticorps afucosylé anti-cd20 et de fludarabine et/ou mitoxantrone | |
MA33758B1 (fr) | Polypeptides anti-tnfr1 stables, domaines variables de l'anticorps, et antagonistes | |
WO2007084541A3 (fr) | Administration centrale de formulations stables d'agents thérapeutiques dans le traitement d'affections du système nerveux central (snc) |